Table 2. Baseline demographics and clinical characteristics of patients receiving GSK1070806.
| GSK1070806 3 mg/kg IV (N = 7) | |
|---|---|
| Age (years), mean (SD) | 58.7 (13.46) |
| Sex, n (%) | |
| Female | 0 (0) |
| Male | 7 (100) |
| Ethnicity, n (%) | |
| Hispanic or Latino | 0 (0) |
| Non-Hispanic or Latino | 7 (100) |
| Height (cm), mean (SD) | 179.1 (9.35) |
| Weight (kg), mean (SD) | 92.97 (16.806) |
| BMI (kg/m2), mean (SD) | 29.20 (6.014) |
| Current medical conditions* | |
| Cardiovascular risk factors, n (%) | |
| Any condition | 7 (100) |
| Hypertension | 7 (100) |
| Hyperlipidemia | 2 (29) |
| Angina pectoris | 1 (14) |
| Diabetes | 1 (14) |
| Renal and urinary disorders, n (%) | |
| Any condition | 5 (71) |
| Glomerulonephritis/autoimmune | 2 (29) |
| Hypertensive nephropathy | 1 (14) |
| Polycystic kidney disease | 1 (14) |
| Sequelae of systemic autoimmunity | 1 (14) |
| Other condition, n (%) | |
| Any condition | 6 (86) |
| Respiratory, thoracic, and mediastinal disorders | 2 (29) |
| Gout | 2 (29) |
| Anemia normocytic | 1 (14) |
| Endocrine disorders | 1 (14) |
| Hepatobiliary disorders | 1 (14) |
| Immune system disorders | 1 (14) |
| Known left ventricular hypertrophy | 1 (14) |
| Musculoskeletal and connective tissue disorders | 1 (14) |
| Psychiatric disorders | 1 (14) |
| Pacemaker inserted | 1 (14) |
| Scleritis | 1 (14) |
| Vascular disorders | 1 (14) |
| Anemia | 1 (14) |
*Current medical conditions were collected as per the protocol but summarized post-hoc; patients may have had more than one current medical condition.